| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3063 |
| Trial ID | NCT05410041 |
| Disease | Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-NK cell |
| Treatment | CD19 CAR-NK cells |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies |
| Year | 2022 |
| Country | China |
| Company sponsor | Beijing Boren Hospital |
| Other ID(s) | BRYY-IIT-LCYJ-2022-003 |
| Cohort 1 | |||||||||||
|
|||||||||||